T1	Participants 881 924	Twenty patients with seborrhoeic dermatitis
T2	Participants 954 1068	11 patients in the pimecrolimus 1% cream group and nine patients in the betamethasone 17-valerate 0.1% cream group
T3	Participants 1833 1920	pimecrolimus group, whereas it was reported in most patients of the betamethasone group
